trans-1-{9-[6-(tert-butyldimethylsilanyloxymethyl)-2-styryl-tetrahydro-furo[3,4-d][1,3]dioxol-4-yl]-9H-purin-6-yl}-3-ethylurea

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: trans-1-{9-[6-(tert-butyldimethylsilanyloxymethyl)-2-styryl-tetrahydro-furo[3,4-d][1,3]dioxol-4-yl]-9H-purin-6-yl}-3-ethylurea
• 英文别名: trans-1-{9-[6-(tert-butyl-dimethyl-silanyloxymethyl)-2-styryl-tetrahydro-furo[3,4-d][1,3]dioxol-4-yl]-9H-purin-6-yl}-3-ethyl-urea；1-(9-((2S,3AR,4R,6R,6aR)-6-(((tert-butyldimethylsilyl)oxy)methyl)-2-((E)-styryl)tetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-9H-purin-6-yl)-3-ethylurea；1-[9-[(2S,3aR,4R,6R,6aR)-6-[[tert-butyl(dimethyl)silyl]oxymethyl]-2-[(E)-2-phenylethenyl]-3a,4,6,6a-tetrahydrofuro[3,4-d][1,3]dioxol-4-yl]purin-6-yl]-3-ethylurea
• 化学式: C₂₈H₃₈N₆O₅Si
• 分子量: 566.732
• InChiKey: SXRWASITGHMUBY-HPTBTYSMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.71
• 重原子数：
  40.0
• 可旋转键数：
  8.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  121.65
• 氢给体数：
  2.0
• 氢受体数：
  9.0

反应信息

• 作为反应物：
  描述：

  trans-1-{9-[6-(tert-butyldimethylsilanyloxymethyl)-2-styryl-tetrahydro-furo[3,4-d][1,3]dioxol-4-yl]-9H-purin-6-yl}-3-ethylurea 生成 Regrelor disodium
  参考文献：
  名称：

  Process for the preparation of 4,6-disubstituted-tetrahydro-furo, thieno, pyrrolo and cyclopenta-[3,4][1,3]dioxoles

  摘要：

  本发明涉及一种合成4,6-二取代四氢呋喃、噻吩、吡咯和环戊-[3,4][1,3]二噁烷（式I）的反式异构体的过程。该过程包括以下步骤：（a）获得式II的化合物，该化合物是顺反异构体的混合物；（b）在包含溶剂和酸的溶液中化学分解式II的化合物，所述酸是氢供体或电子对受体，使顺式异构体分解并得到式I的化合物。本发明制备的化合物在治疗与血小板聚集和/或血小板激活有关的疾病或症状中有用。

  公开号：

  US07741473B2
• 作为产物：
  描述：

  trans-9-[6-(tert-butyldimethylaminosilanoxymethyl)-2-styryl-tetrahydro-furo[3,4-d][1,3]dioxol-4-yl]-9H-purin-6-ylamine 生成 trans-1-{9-[6-(tert-butyldimethylsilanyloxymethyl)-2-styryl-tetrahydro-furo[3,4-d][1,3]dioxol-4-yl]-9H-purin-6-yl}-3-ethylurea
  参考文献：
  名称：

  Process for the preparation of 4,6-disubstituted-tetrahydro-furo, thieno, pyrrolo and cyclopenta-[3,4][1,3]dioxoles

  摘要：

  本发明涉及一种合成4,6-二取代四氢呋喃、噻吩、吡咯和环戊-[3,4][1,3]二噁烷（式I）的反式异构体的过程。该过程包括以下步骤：（a）获得式II的化合物，该化合物是顺反异构体的混合物；（b）在包含溶剂和酸的溶液中化学分解式II的化合物，所述酸是氢供体或电子对受体，使顺式异构体分解并得到式I的化合物。本发明制备的化合物在治疗与血小板聚集和/或血小板激活有关的疾病或症状中有用。

  公开号：

  US07741473B2

文献信息

• Adenosine analogues as inhibitors of P2Y12 receptor mediated platelet aggregation
  作者：James G. Douglass、J. Bryan deCamp、Emilee H. Fulcher、William Jones、Sanjoy Mahanty、Anna Morgan、Dima Smirnov、José L. Boyer、Paul S. Watson

  DOI：10.1016/j.bmcl.2008.01.038

  日期：2008.3

  Modified adenosine derivatives may lead to the development of P2Y(12) antagonists that are potent, selective, and bind reversibly to the receptor. Analogues of 2',3'-trans-styryl acetal-N6-ureido-adenosine monophosphate were prepared by modification of the 5'-position. The resulting analogues were tested for P2Y(12) antagonism in a platelet aggregation assay.

  修饰的腺苷衍生物可能导致有效，选择性和可逆地与受体结合的P2Y（12）拮抗剂的发展。通过修饰5′-位制备2′，3′-反式-苯乙烯基乙缩醛-N6-脲基-腺苷单磷酸酯的类似物。在血小板聚集试验中测试了所得类似物对P2Y（12）的拮抗作用。
• METHOD OF TREATING INFLAMMATION
  申请人：Brubaker Kurt E.

  公开号：US20070249556A1

  公开（公告）日：2007-10-25

  This invention provides methods of preventing and/or treating diseases or conditions associated with inflammation in a mammal, particularly a human. The method comprises administering to a mammal in need thereof an effective amount of a compound of Formula I, IA, or IB, wherein said amount is effective to inhibit inflammation. The invention also provides methods for inhibiting chemotaxis of leukocytes.

  本发明提供了一种预防和/或治疗与哺乳动物（特别是人类）炎症相关的疾病或病症的方法。该方法包括向需要的哺乳动物投与公式I、IA或IB化合物的有效量，其中该量足以抑制炎症。本发明还提供了抑制白细胞趋化的方法。
• Process for the preparation of 4,6-disubstituted-tetrahydro-furo, thieno, pyrrolo and cyclopenta-[3,4][1,3]dioxoles
  申请人：Inspire Pharmaceuticals, Inc.

  公开号：US07741473B2

  公开（公告）日：2010-06-22

  The present invention is directed to a processes for the synthesis of trans isomer of 4,6-disubstituted-tetrahydro-furo, thieno, pyrrolo and cyclopenta-[3,4][1,3]dioxoles (Formula I). The process comprises the steps of: (a) obtaining a compound of Formula II, which is a mixture of cis and trans-diastereomers, and (b) chemically decomposing the compound of Formula II in a solution comprising a solvent and an acid that is a hydrogen donor or an electron pair acceptor, whereby the cis diastereomer is decomposed and the compound of Formula I is obtained. The compounds prepared by the present invention are useful in treating diseases or conditions associated with platelet aggregation and/or platelet activation.

  本发明涉及一种合成4,6-二取代四氢呋喃、噻吩、吡咯和环戊-[3,4][1,3]二噁烷（式I）的反式异构体的过程。该过程包括以下步骤：（a）获得式II的化合物，该化合物是顺反异构体的混合物；（b）在包含溶剂和酸的溶液中化学分解式II的化合物，所述酸是氢供体或电子对受体，使顺式异构体分解并得到式I的化合物。本发明制备的化合物在治疗与血小板聚集和/或血小板激活有关的疾病或症状中有用。
• WO2006/105529
  申请人：——

  公开号：——

  公开（公告）日：——